Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$25.63
-$0.08 (-0.31%)
At close: Oct 30, 2026, 4:00 PM ET
$23.20
-$2.43 (-9.48%)
Pre-market:
Nov 2, 2026, 7:45 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Net Income | -28.94M | -26.87M |
Depreciation & Amortization | 110K | 63K |
Stock-Based Compensation | n/a | 1.19M |
Other Working Capital | 103K | -3.04M |
Other Non-Cash Items | 2.74M | -123K |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | 10K | -4.16M |
Operating Cash Flow | -26.08M | -29.89M |
Capital Expenditures | -269K | -318K |
Cash Acquisitions | n/a | n/a |
Purchase of Investments | -134.83M | n/a |
Sales Maturities Of Investments | 16.39M | 55.34M |
Other Investing Acitivies | n/a | n/a |
Investing Cash Flow | -118.71M | 55.02M |
Debt Repayment | -208K | 15M |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | n/a | -163K |
Financial Cash Flow | 316.67M | 14.86M |
Net Cash Flow | 171.89M | 40M |
Free Cash Flow | -26.35M | -30.21M |
Adj. Free Cash Flow | -26.35M | -31.4M |
Maintenance CapEx | -110K | -63K |
Growth CapEx | -159K | -255K |
Owner Earnings | -26.19M | -29.95M |
Add to Watchlist
Select watchlists to add or remove AVLN